CMS proposes CARE rule to cut Medicare and Medicaid red tape; scope still unclear

What happened

CMS has issued proposed rule CMS-3484-P, titled 'Cutting Administrative Requirements for Excellence in Patient Care (CARE)'. The title and an accompanying fact sheet place it across the Medicare and Medicaid programs. That is all the material available to us confirms. The specific provisions are not yet clear from what we have seen.

A proposed rule is the first formal step in US rulemaking. The agency publishes draft regulatory text and rationale and invites public comment. It then considers the comments before deciding whether and how to finalise. Nothing in a proposal is binding on payers, providers or manufacturers until a final rule is issued and takes effect.

What we do not know yet

The records do not say which requirements the rule would cut, which provider or plan types it targets, or how long the comment period runs. They give no effective date and no estimate of savings or burden reduction. We will not guess at any of these.

That matters for market access teams. 'Administrative requirements' could mean many things in a program as large as Medicare and Medicaid. Until the text has been read, it is not known whether the rule touches anything that affects drug coverage, utilisation management, reporting or manufacturer obligations, or whether it is confined to provider-facing operational rules. The headline alone does not answer that question.

A useful contrast: what administrative load looks like in Italy

The related records come from a different system, but they show how much routine administrative work sits behind reimbursement. On 6 November 2026, Italy's medicines agency AIFA published a batch of changes to its product monitoring registries. These web-based registries are tied to national health service reimbursement of specific medicines.

The updates are granular. AIFA activated the registry for Voranigo (vorasidenib) and published clinical forms, with reimbursed use for IDH-mutant grade 2 glioma possible from 6 November. It revised the Rybrevant (amivantamab) registries for two lung cancer indications to add subcutaneous schedules and their marketing authorisation numbers. It also changed how carboplatin-containing combinations are selected on the request form for first-line EGFR exon 20 insertion disease.

Other changes followed the same pattern. The Tevimbra (tislelizumab) registries gained a six-weekly dosing schedule and new AIC codes, following Determination PRES/1512/2026. The Lunsumio registry for relapsed or refractory follicular lymphoma added subcutaneous dosing and new marketing authorisation numbers, following Determination PRES/1504/2026. The Imfinzi (durvalumab) registry for resectable NSCLC added a carboplatin-gemcitabine option to the neoadjuvant phase. The Enhertu registries for breast and gastric cancer removed a block on treating patients with active, symptomatic or uncontrolled brain metastases.

None of this is connected to the CMS proposal, and the two systems work very differently. The comparison is only an illustration. Even a modest label or dosing change can require registry, coding and form updates before patients can be treated under reimbursement. Teams in any market should count that operational work as part of access, not as an afterthought.

Who is affected

The proposal is relevant first to US market access, government affairs and reimbursement teams that track Medicare and Medicaid policy. Medical affairs and field reimbursement colleagues may be affected indirectly if the final rule changes provider workflows. How far any of this reaches manufacturers is unknown until the text is analysed.

For teams with European launches, the AIFA records are more immediately practical. Subcutaneous formulations, new dosing intervals and changed treatment-eligibility rules each triggered registry changes in Italy on a single day. Companies with products in these classes should confirm that their Italian registry entries, AIC codes and prescriber instructions match the current forms.

What to watch

For CMS-3484-P, the first task is to read the proposed text and the fact sheet. Then identify the comment deadline, the affected provisions and any provisions that touch drug coverage or manufacturer-facing processes. If the rule is relevant, decide whether to file comments directly or through a trade association.

Also watch whether the agency quantifies the burden it expects to remove, and whether any provisions would shift work onto other parties, such as plans, states or manufacturers, rather than eliminating it. Neither point can be assessed from the current records.

On the Italian side, watch for further registry revisions as new formulations and regimens reach reimbursement. Each change may bring its own determination number and effective date, so teams should track the AIFA notices closely rather than rely on the original reimbursement decision.